Nepal, June 9 -- An experimental drug empowered by artificial intelligence to identify a novel therapeutic target for a severe lung disease has demonstrated promising safety and efficacy results in its phase two clinical trial, according to a research paper released this week.

The outcome marks the world's most advanced clinical trial progress for an AI-driven drug discovery and has boosted confidence in tapping into AI's potential in expediting drug development, according to Insilico Medicine, a global biotech company, and a Chinese researcher involved in the experiment.

The novel drug, named Rentosertib, features a newly discovered protein target known as TNIK, which was identified and optimized through the assistance of the company's...